Hepatitis D - Pipeline Review, H1 2016

Published: Apr, 2016 | Pages: 61 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Hepatitis D - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Hepatitis D - Pipeline Review, H1 2016', provides an overview of the Hepatitis D pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Hepatitis D, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hepatitis D and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hepatitis D
- The report reviews pipeline therapeutics for Hepatitis D by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Hepatitis D therapeutics and enlists all their major and minor projects
- The report assesses Hepatitis D therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Hepatitis D

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Hepatitis D
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Hepatitis D pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope 
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Content 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Hepatitis D Overview 7
Therapeutics Development 8
Pipeline Products for Hepatitis D - Overview 8
Pipeline Products for Hepatitis D - Comparative Analysis 9
Hepatitis D - Therapeutics under Development by Companies 10
Hepatitis D - Therapeutics under Investigation by Universities/Institutes 11
Hepatitis D - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Hepatitis D - Products under Development by Companies 14
Hepatitis D - Products under Investigation by Universities/Institutes 15
Hepatitis D - Companies Involved in Therapeutics Development 16
Alnylam Pharmaceuticals, Inc. 16
BioDiem Ltd 17
Eiger BioPharmaceuticals, Inc. 18
Globeimmune, Inc. 19
REPLICor Inc. 20
SomaGenics, Inc. 21
Spring Bank Pharmaceuticals, Inc. 22
Hepatitis D - Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Target 24
Assessment by Mechanism of Action 26
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 32
ALN-HDV - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
GI-18000 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
hepatitis D vaccine - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
lonafarnib - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Myrcludex-B - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
REP-2139 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
REP-2165 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
RNAi Oligonucleotide for Hepatitis D - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
SB-9200 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
vanitaracin A - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Hepatitis D - Recent Pipeline Updates 46
Hepatitis D - Dormant Projects 54
Hepatitis D - Product Development Milestones 55
Featured News & Press Releases 55
Apr 04, 2016: Replicor to Make Three Presentations at EASL 2016 55
Mar 30, 2016: Eiger BioPharmaceuticals Announces Abstracts and Presentations of Lonafarnib Data in Hepatitis Delta at the European Association for the Study of the Liver Meeting 55
Mar 23, 2016: Maxwell Biotech Venture Fund's Portfolio Company Hepatera Announces Start of Phase 2b clinical trial of Myrcludex B, a Novel Entry Inhibitor for Treatment of Chronic HBV and HDV Infection 56
Mar 14, 2016: Eiger BioPharmaceuticals Announces Completion of Enrollment of Phase 2 LOWR HDV - 4 (LOnafarnib With Ritonavir in Hepatitis Delta Virus - 4) Study at Hannover Medical School 56
Jan 19, 2016: Eiger BioPharmaceuticals Announces Completion of Enrollment of Phase 2 LOWR HDV - 3 (LOnafarnib With Ritonavir in Hepatitis Delta Virus - 3) Study at National Institutes of Health 57
Jan 06, 2016: Eiger BioPharmaceuticals Announces First Patient Dosed in Phase 2 LOWR HDV - 4 (LOnafarnib With Ritonavir in Hepatitis Delta Virus - 4) Study at Hannover Medical School in Hannover, Germany 57
Jul 20, 2015: The Lancet Infectious Diseases Journal Publishes Results of Phase 2 Study of Lonafarnib in Hepatitis Delta Virus Infected Patients 58
Jun 30, 2015: Replicor Discloses Updated Clinical Trial Data to the Global Virus Hepatitis Summit in Berlin 58
Jun 10, 2015: Replicor to Present at the Israel Association for the Study of Liver Conference and the Global Virus Hepatitis Summit in Berlin in June 59
Apr 29, 2015: Significant Reduction of HBsAg and HDV RNA by REP 2139-Ca in Caucasian Patients with HBV / HDV Co-Infection 59
Appendix 60
Methodology 60
Coverage 60
Secondary Research 60
Primary Research 60
Expert Panel Validation 60
Contact Us 60
Disclaimer 61

List of Tables

Number of Products under Development for Hepatitis D, H1 2016 8
Number of Products under Development for Hepatitis D - Comparative Analysis, H1 2016 9
Number of Products under Development by Companies, H1 2016 10
Number of Products under Investigation by Universities/Institutes, H1 2016 11
Comparative Analysis by Clinical Stage Development, H1 2016 12
Comparative Analysis by Early Stage Development, H1 2016 13
Products under Development by Companies, H1 2016 14
Products under Investigation by Universities/Institutes, H1 2016 15
Hepatitis D - Pipeline by Alnylam Pharmaceuticals, Inc., H1 2016 16
Hepatitis D - Pipeline by BioDiem Ltd, H1 2016 17
Hepatitis D - Pipeline by Eiger BioPharmaceuticals, Inc., H1 2016 18
Hepatitis D - Pipeline by Globeimmune, Inc., H1 2016 19
Hepatitis D - Pipeline by REPLICor Inc., H1 2016 20
Hepatitis D - Pipeline by SomaGenics, Inc., H1 2016 21
Hepatitis D - Pipeline by Spring Bank Pharmaceuticals, Inc., H1 2016 22
Assessment by Monotherapy Products, H1 2016 23
Number of Products by Stage and Target, H1 2016 25
Number of Products by Stage and Mechanism of Action, H1 2016 27
Number of Products by Stage and Route of Administration, H1 2016 29
Number of Products by Stage and Molecule Type, H1 2016 31
Hepatitis D Therapeutics - Recent Pipeline Updates, H1 2016 46
Hepatitis D - Dormant Projects, H1 2016 54